According to the Zafgen case study, "obesity has emerged as one of the most serious healthcare problems in recent history, driving waves of associated diseases including coronary artery disease, type 2 diabetes, and certain types of cancer. Recent projections indicate that by 2020, over 40 percent of the adult population will be obese, and diseases like type 2 diabetes will increase in prevalence accordingly. Total health-care costs attributable to obesity/overweight are anticipated to exceed $860 billion by 2030, accounting for 16-18% of total US health-care costs."
Zafgen is dedicated to developing novel therapeutics to treat obesity. In this case study, you can learn more about what Zafgen is doing to develop an innovative product that will lead to weight loss and metabolic improvements.
To learn more about innovation in pharma, click here.